SURPASS: Mechanism of action of ADP-A2M4CD8

ADP-A2M4CD8 Mechanism of Action (Next-generation SPEAR T-cell)Подробнее

AACR Annual Virtual Meeting 2021 - Focus on our SURPASS and ADP-A2AFP trialsПодробнее

SURPASS: evaluating the next-generation of SPEAR T-cell therapyПодробнее

Adaptimmune reports updated SURPASS data at ESMO 2021Подробнее

SURPASS-2: investing ADP-A2M4CD8 SPEAR T-cell therapy to treat esophageal and GEJ cancersПодробнее

SURPASS: ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapyПодробнее

SURPASS: ADP-A2M4CD8 T-cell receptor T-cell therapy and pembrolizumab in UCПодробнее

SITC 2020 - Adaptimmune's SURPASS PosterПодробнее

Structures of human PRC2 with its cofactors AEBP2 and JARID2Подробнее

Update on Adaptimmune's SURPASS Family of TrialsПодробнее

SPEAR T-cells Derived from Stem Cells Kill Cancer Targets in vitro - data from ASGCT 2020Подробнее

AdaptimmuneПодробнее

ADP-A2AFP data presented at the 2020 International Liver CongressПодробнее

SPEARHEAD-2 trial design: combining SPEAR T-cells with pembrolizumabПодробнее

Danton Ivanochko: a chemical probe for PRDM9Подробнее

Adaptimmune SPEAR T-Cell Mechanism of Action VideoПодробнее

Targeting macrophages for solid tumor immunotherapyПодробнее

Proteomist® DT II - High Throughput Protein ExpressionПодробнее